The effect of age at first dose of a measles-containing vaccine on measles humoral immunity: a retrospective cohort study, Canada, 2014 to 2016

BACKGROUNDCanada eliminated measles in 1998; however, large outbreaks have been recently reported, and elimination status was lost in 2025.AIMWe aimed to estimate the effect of age at first dose of measles-containing vaccine (MCV1) on measles IgG concentration and seronegativity among two-dose recipients nearly two decades after vaccination.METHODSWe conducted a retrospective cohort study of 10,766 twice-vaccinated individuals tested for measles IgG from 2014 to 2016 in Ontario, Canada. We predicted measles IgG concentration and seronegativity using thresholds of < 275 mIU/mL, < 200 mIU/mL and ≤ 120 mIU/mL.RESULTSA 1-month increase in age at MCV1 (between 12 and 15 months) was associated with 13.7% (95% confidence interval (CI): 7.1-20.8) higher predicted mean measles IgG concentration for females born after elimination and 9.2% (95% CI: 6.8-11.6) for females born before elimination. Depending on the seronegativity threshold and the measles elimination status at birth, a 1-month increase in age at MCV1 (between 12 and 15 months) was associated with lower odds ratio of seronegativity ranging from 0.74 (95% CI: 0.63-0.85) to 0.87 (95% CI: 0.57-1.27). Using the lowest threshold (≤ 120 mIU/mL) and the longest follow-up period (24 years post-MCV1), we predicted that 4.1% (95% CI: 2.7-6.1) of females vaccinated with MCV1 at 15 months of age would be seronegative, compared with 9.6% (95% CI: 7.4-12.3) of those vaccinated at 12 months.DISCUSSIONDelaying MCV1 to older ages (13-15 months) may result in an absolute decrease as large as 6% in the percentage of seronegative individuals, potentially increasing the likelihood of maintaining herd immunity.

Authors

Institutions

Publication Details

Journal
Eurosurveillance
Published
2026-11-12
DOI
https://doi.org/10.2807/1560-7917.es.2026.31.45.2600105
Citations
1
Primary Topic
Virology and Viral Diseases
Type
article
Field-Weighted Citation Impact
3.33
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The effect of age at first dose of a measles-containing vaccine on measles humoral immunity: a retrospective cohort study, Canada, 2014 to 2016

Kevin Antoine Brown, Shelly Bolotin, Natasha Sarah Crowcroft, Jeffrey C. Kwong et al.
1 citations
Eurosurveillance
Virology and Viral Diseases
3.33
article

The effect of age at first dose of a measles-containing vaccine on measles humoral immunity: a retrospective cohort study, Canada, 2014 to 2016

Kevin Antoine Brown, Shelly Bolotin, Natasha Sarah Crowcroft, Jeffrey C. Kwong, Archchun Ariyarajah, John Wang
article en
1 citations

Abstract

BACKGROUNDCanada eliminated measles in 1998; however, large outbreaks have been recently reported, and elimination status was lost in 2025.AIMWe aimed to estimate the effect of age at first dose of measles-containing vaccine (MCV1) on measles IgG concentration and seronegativity among two-dose recipients nearly two decades after vaccination.METHODSWe conducted a retrospective cohort study of 10,766 twice-vaccinated individuals tested for measles IgG from 2014 to 2016 in Ontario, Canada. We predicted measles IgG concentration and seronegativity using thresholds of < 275 mIU/mL, < 200 mIU/mL and ≤ 120 mIU/mL.RESULTSA 1-month increase in age at MCV1 (between 12 and 15 months) was associated with 13.7% (95% confidence interval (CI): 7.1-20.8) higher predicted mean measles IgG concentration for females born after elimination and 9.2% (95% CI: 6.8-11.6) for females born before elimination. Depending on the seronegativity threshold and the measles elimination status at birth, a 1-month increase in age at MCV1 (between 12 and 15 months) was associated with lower odds ratio of seronegativity ranging from 0.74 (95% CI: 0.63-0.85) to 0.87 (95% CI: 0.57-1.27). Using the lowest threshold (≤ 120 mIU/mL) and the longest follow-up period (24 years post-MCV1), we predicted that 4.1% (95% CI: 2.7-6.1) of females vaccinated with MCV1 at 15 months of age would be seronegative, compared with 9.6% (95% CI: 7.4-12.3) of those vaccinated at 12 months.DISCUSSIONDelaying MCV1 to older ages (13-15 months) may result in an absolute decrease as large as 6% in the percentage of seronegative individuals, potentially increasing the likelihood of maintaining herd immunity.

EurosurveillanceVol. 31(45)
Public Health Agency of Canada (CA), University of Toronto (CA), Public Health Ontario (CA), Institute for Clinical Evaluative Sciences (CA)
Openalex Percentile: Top 15%
Virology and Viral Diseases
3.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon